-
-
-
-
-
-
-
Reata Pharma (RETA) Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone
-
-
-
-
-
-
-
Reata Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Discuss Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
-
-
-
-
-
-
-
Reata Announces FDA Accepted for Filing the NDA for Bardoxolone for the Treatment of Patients With Chronic Kidney Disease Caused by Alport Syndrome
-
15,423 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

